source
- BioCryst to rely on external partnerships after ending internal discovery programsBioCryst Pharmaceuticals CEO Charlie Gayer told Fierce that the company remains committed to science and research even as it shuts down its internal discovery efforts. Earlier this year the firm’s…
- Zealand Pharma sells its rights to Takeda's rusfertide for $100 million ahead of FDA decisionZealand Pharma has agreed to sell its economic interest in rusfertide, a peptide drug being developed by Takeda and Protagonist Therapeutics, for $100 million. The transaction comes as the FDA rev…